Skip to main content
. 2019 Apr 8;21(7):890–900. doi: 10.1093/neuonc/noz060

Fig. 2.

Fig. 2

Long-term administration of valGCV is more efficient compared with short-term GCV treatment in vivo. (A) Representative MRI (T2 rapid acquisition with relaxation enhancement) images are shown. The solid tumor regions are marked with dashed lines. (B) Kaplan–Meier survival analysis: 3-month valGCV treatment has a significant survival benefit compared with the 3-week GCV treatment (P = 0.008).